Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gaxilose is a synthetic disaccharide and small molecule diagnostic agent used primarily for the noninvasive diagnosis of hypolactasia (lactase deficiency), which underlies lactose intolerance. Structurally, it is a close analogue of lactose (specifically 4-O-β-D-galactopyranosyl-d-xylose). After oral administration, gaxilose is hydrolyzed in the intestine by the enzyme lactase into galactose and xylose. The amount of xylose excreted in urine after ingestion directly reflects intestinal lactase activity and thus serves as a quantitative marker for diagnosing hypolactasia. Gaxilose has been approved for use as a diagnostic tool in some countries under brand names such as LacTEST and Lactophan[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gaxilose.